Quest Diagnostics (NYSE:DGX) reported an insider stock transaction by Karthik Kuppusamy, senior vice president of Clinical Solutions. According to a Form 4 filing with the Securities and Exchange Commission, Kuppusamy sold 2,628 shares of Quest Diagnostics common stock on March 4, 2026, at a per-share price of $204.86, yielding proceeds of approximately $538,372.
The sale occurred while Quest shares were trading near their 52-week high of $213.50 and reflected the stock’s year-to-date gain of roughly 18%.
The same Form 4 filing shows that Kuppusamy also acquired 6,200 shares on March 4, 2026, at the identical price of $204.86. That acquisition, valued at $1,270,132, was connected to the settlement of a performance stock award.
After these transactions were recorded, Kuppusamy directly holds 13,441 shares of Quest Diagnostics common stock. In addition to his direct holdings, he has an indirect ownership of 358 shares held in trust and 1,658 shares held through a 401(k) plan, as reported in the filing.
Valuation and analyst tools
InvestingPro analysis included in the filing summary indicates that Quest Diagnostics appears overvalued at current market levels. The note highlights that Quest has increased its dividend for 14 consecutive years and that this is one of multiple InvestingPro Tips available for DGX. InvestingPro also references an available Pro Research Report for Quest Diagnostics and more than 1,400 other U.S. equities for investors seeking additional detail.
Recent corporate developments
Quest Diagnostics published its fourth-quarter 2025 earnings that exceeded analyst expectations. The company reported earnings per share of $2.42 versus the forecasted $2.36, and revenue of $2.81 billion versus an anticipated $2.75 billion.
In product developments, Quest Diagnostics introduced the Quest AI Companion, an AI-powered capability integrated into the MyQuest mobile app and portal. The tool, which is powered by Google’s Gemini models, enables users to analyze their laboratory test results and can access and analyze up to five years of an individual’s Quest lab data to identify trends and patterns.
On the leadership front, Quest Diagnostics named Benjamin Beauvalot as senior vice president, chief strategy and M&A officer. Beauvalot joins Quest with more than 20 years of experience in business strategy, mergers and acquisitions, and transformation from his previous role at Danaher Corporation.
These concurrent items - an insider sale and simultaneous award settlement, a valuation assessment from InvestingPro, stronger-than-expected quarterly financials, the rollout of an AI-driven patient data tool, and a strategic hire - outline recent activity at Quest Diagnostics but leave market participants to assess how each factor should be weighted in investment decisions.